Abstract 3914
Background
Sarcoma is a rare disease affecting both bone and connective tissue and with over 100 pathologic entities, diagnosis can be difficult. Approximately one third of sarcoma patients however are characterised by recurrent genetic alterations mainly chromosomal translocations, which result in fusion genes, and gene amplifications. Fusion genes are highly useful diagnostic markers and are currently identified in the clinical setting using FISH/RT-PCR. Conversely, conclusive results cannot be achieved in up to 25% of fusion positive patients using these methods. Next generation sequencing (NGS) is a promising tool that can improve soft-tissue sarcoma diagnosis.
Methods
A novel sarcoma-specific NGS gene capture panel containing probes for 90 fusion genes and 7 genes with frequent copy number changes was designed, optimised and validated in order to improve fusion-positive sarcoma diagnosis. Genomic DNA was extracted from 92 well-characterised FFPE samples and libraries prepared using the KAPA Hyperplus kit (Roche) and hybridised using the SeqCap Hybridisation kit (Roche) and sequenced on a NextSeq platform (Illumina).
Results
Sarcoma specific translocations or gene amplifications were identified in 92 out of 94 cases giving the targeted gene panel a sensitivity of approximately 98% and specificity of 100% (Table).Table:
1717P Sarcoma tumour types and number of cases with structural variants or copy number variations detected
Soft Tissue Tumour Type | No. of cases | SV/CNV detected |
---|---|---|
Synovial Sarcoma | 25 | 25 |
Alveolar Rhabdomyosarcoma | 6 | 6 |
Well/Dedifferentiated Liposarcoma | 9 | 8 |
Intimal Sarcoma | 1 | 1 |
Desmoplastic Small Round Cell Tumour (DSRCT) | 2 | 2 |
Ewing’s Sarcoma | 11 | 11 |
Inflammatory Myofibroblastic Tumour | 2 | 2 |
Myxoid Liposarcoma | 10 | 10 |
Chondroid Lipoma | 1 | 1 |
Clear Cell Sarcoma | 4 | 4 |
Epithelioid Haemangioendothelioma | 2 | 1 |
Low-grade Fibromyxoid Sarcoma | 3 | 3 |
Nodular Fasciitis | 1 | 1 |
Alveolar Soft Part Cell Sarcoma | 1 | 1 |
Congenital Fibrosarcoma | 2 | 2 |
Solitary Fibrous Tumour | 2 | 2 |
Aneurysmal Bone Cyst | 1 | 1 |
BCOR-CCNB3 Sarcoma | 1 | 1 |
Extraskeletal Myxoid Chondrosarcoma | 5 | 5 |
Mesenchymal Chondrosarcoma | 2 | 2 |
Dermatofibrosarcoma Protuberans (DFSP) | 3 | 3 |
TOTAL | 94 | 92 |
Conclusions
To the best of our knowledge this is the first sarcoma-specific NGS panel validated in FFPE-derived genomic DNA. It is at least as sensitive and specific as the combination of FISH and RT-PCR and can be implemented in routine clinical diagnostic workflows. We are currently investigating whether fusion genes can be detected in plasma using ctDNA from 14 patients and results will be reported at the conference.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
David Gonzalez de Castro.
Funding
Sarcoma UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract